Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 7Lymphoid 6Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Myeloid 1Genitourinary 1Classical hematology 1

Conditions

Sarcoma, Myeloid 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1

Interventions

Specimen Handling 39Magnetic Resonance Spectroscopy 33Cyclophosphamide 30Doxorubicin 24Biopsy 24pembrolizumab 22Temozolomide 22Radiotherapy 20Radiation 19X-Rays 18Nivolumab 15Vincristine 13Irinotecan 13fludarabine 12Phantoms, Imaging 12Ifosfamide 12Gemcitabine 12atezolizumab 11cabozantinib 10Ipilimumab 9Bevacizumab 9liposomal doxorubicin 8Surgical Procedures, Operative 8Paclitaxel 8Immunoglobulin G 8Etoposide 8Dactinomycin 7Carboplatin 7palbociclib 6olaparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
pegylated granulocyte colony-stimulating factor × Sarcoma × 90 days × Clear all
NCT04797767 2026-04-17

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

University of Washington

Phase 1/2 Recruiting
62 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡